PRINCETON, NJ, November 02, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. OYSTER a commercial-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class pharmaceutical therapies for the treatment of eye diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022, after market close will announce . The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. ET.

Conference call details
To access the live call by phone, please register here to receive dial-in data or to select a callback.

Webcast Details
The webcast will be made available on the company’s website at www.oysterpointrx.com under the heading “Events & Presentations”. A replay of the webcast will be available on the company’s website.

About Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class pharmaceutical therapies for the treatment of eye diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYA® (varenicline solution) nasal spray. Oyster Point Pharma has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point Pharma continually strives to advance breakthrough science and deliver therapies designed to address the unmet needs of patients with eye diseases and the eye care professionals who care for them. For more information visit www.oysterpointrx.com and keep following @OysterPointRx Twitter and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which reflect Oyster Point Pharma, Inc.’s current beliefs, expectations and assumptions regarding the future of the company…